Two angiostatic fusion proteins (hAE and hEA), differing in tandem connection manners, were constructed from human angiostatin (hAS) and endostatin (hES) proteins. These fusion proteins were then evaluated for synergistic antiangiogenic properties. The 65 kDa secreted fusion proteins, expressed in Pichia pastoris, were verified by both mass analysis and Western blotting assay. Luciferase reporter gene assay, using a VEGF promoter, revealed that the angiostatin-endostatin fusion protein (hAE), and its corresponding fusion gene delivery on human microvascular endothelial cells (HMEC-1), resulted in a more potent synergistic antiangiogenic effect than the endostatin-angiostatin fusion protein (hEA). These results suggest that the orientation of the fusion genes in hAS and hES might be an important factor in the development of therapeutic proteins.
Multicellular organisms require oxygen and nutrients for their survival. Hence, these types of organisms must recruit new blood vessels via vasculogenesis and angiogenesis in order to grow beyond the oxygen diffusion field [4] . Moreover, it has been revealed that angiogenesis plays an important role in the growth and progression of cancer [17] . Tumor growth and metastasis are angiogenesis dependent, and thus blocking angiogenesis could be a strategy utilized to arrest tumor growth [7] .
Numerous studies had been conducted in the past decades. As a result, several potentially negative regulators of angiogenesis have been isolated, such as angiostatin [14] , endostatin [16] , vasostatin [17] , thrombospondin [6] , and many more from a variety of sources. Each of these numerous angiogenesis inhibitors have potent clinical implications and represent a novel strategy for anticancer therapy, which targets the tumor vessels instead of the cancer cells.
Angiostatin (a 38 kDa proteolytic fragment containing five kringle domains of human plasminogen), and endostatin (a 20 kDa carboxyl-terminal fragment of collagen XVIII), are two of the best known potent antiangiogenic proteins that have individually demonstrated antitumor activity in multiple murine tumor models, both in the prevention and the treatment of established tumors [1, 3, 8, 15, 22] . These proteins appear to induce apoptosis in tumor cells, but do not have cytotoxic effects on other cell types, including endothelial cells.
The combination of angiostatin and endostatin has been shown to exhibit synergistic antiangiogenic and antitumor effects when the genes encoding these proteins are delivered to tumor cells by gene transfer [10, 11, 12, 18, 23, 25] . Moreover, the construction of a murine angiostatinendostatin fusion gene has been shown to more greatly enhance antiangiogenic activity on human umbilical vein endothelial cell (HUVEC) tube formation in vitro, when compared with either angiostatin or endostatin alone [19] . Thus, it has been inferred from previous studies that a combination of antiangiogenic factors may demonstrate the additive, or synergistic inhibition, of angiogenesis and tumor growth. Therefore, it was hypothesized that chimeric human antiangiogenic proteins, such as hAE (human angiostatin-endostatin fusion) or hEA (human endostatinangiostatin fusion), might exhibit an enhanced antitumor response.
Current gene therapy is experimental and has not proven very successful in clinical trials because of the weak in vivo therapeutic effect. Therefore, chimeric human hybrid proteins expressed in the Pichia pastoris systems might be an alternative approach for clinical trials hoping for the exhibition of a stronger therapeutic effect [26] . Recently, hybrid proteins of human angiostatin and endostatin were expressed in E. coli and evaluated [24] . However, what remains unknown is whether the orientation of the two proteins in fusion constructs affects the overall synergistic effects of these fusion proteins. Here, we expressed two soluble fusion proteins (hAE and hEA) in Pichia pastoris, and evaluated whether their orientation affected their antiangiogenic properties, through the use of the VEGF promoter assay.
MATERIALS, METHODS, AND RESULTS
Approximately, 0.6 kb of human angiostatin (hAS) and 1.0 kb of endostatin (hES) genes were obtained by PCR amplification from the human fetal cDNA Library (Clontech 639338, U.S.A.) (Fig. 1) . The specific primers used for the PCR amplification of the human angiostatin genes (GenBank Accession No. NM000301), and human endostatin genes (GenBank Accession No. NM130445), are listed in Table 1 . PCR was carried out using Pyrobest DNA Polymerase . Two different fusion genes with different orientations (hAS-hES, named hAE; and hES-hAS, named hEA) were constructed using internal fusion PCR primers ( Table 1 ). The PCR products were then subcloned into pGEM T-easy vectors. Consequently, 1.6 kb of the fusion constructs (hAE and hEA) were further analyzed with DNA sequencing, and its deduced amino acid sequences were found to be identical with the anticipated sequences.
In order to subclone human endostatin-angiostatin fusion genes into P. pastoris expression pPICZαA vectors, the inserted genes were amplified using specific primer sets; hES (hES-F2/hES-R2), hAS (hAS-F2/hAS-R2), hEA (hES-F2/hAS-R2), and hAE (hAS-F2/hES-R2), containing EcoRI and XbaI restriction sites. Recombinant pGEM T-easy vectors harboring the hES, hAS, hEA, and hAE genes were used as templates. PCR products were purified by using an agarose gel extraction kit (Intron, Korea) and directly ligated into the pGEM T-easy vector system. Ligated DNAs were transformed into E. coli strain XL10-Gold. 
The resulting recombinant plasmids, with two single genes (hES, hAS) and two hybrid genes (hAE, hEA), were analyzed by restriction analysis and DNA sequencing. The positive clones, T-easy/hES, hAS, hEA, and hAE, were digested with EcoRI and XbaI. The 0.6 kb, 1.1 kb, and 1.6 kb gene fragments were purified from a 0.8% agarose gel by using an agarose gel elution kit and directly ligated into the pPICZαA plasmid (Invitrogen, U.S.A.), previously treated with the same restriction enzymes. The constructed recombinant plasmids were designated as pPICZα/hES, pPICZαA/hAS, pPICZαA/ hEA, and pPICZαA/hAE, respectively. The ligated DNA was again transformed into E. coli strain XL10-Gold.
Transformation of P. pastoris was performed as described in previous literature [20] . Recombinant pPICZαA harboring the hES, hAS, hEA, and hAE genes were electroporated into P. pastoris strain SMD1168H. Pichia transformants were selected for growth on YPD plates supplemented with Zeocin (100 µg/ml). After initial screen on Zeocin resistance, the Pichia transformant with a high copy number of target genes was selected by its growth on 8-fold Zeocin (800 µg/ml) YPD plates. The target gene integration was confirmed by yeast colony PCR. PCR analyses showed that the hES, hAS, hEA, and hAE genes were successfully transformed into the chromosome of P. pastoris strain SMD1168H (data not shown).
Expression and purification of the recombinant proteins in the methylotropic yeast P. pastoris, using α-factor secretory signal, subsequently followed. The proteins of hES, hAS, hEA, and hAE were analyzed by SDS polyacrylamide gel electrophoresis (Fig. 2A) . The recombinant human endostatin and angiostatin proteins were detected at the range of 25 kDa and 55 kDa, respectively. However, the expression levels of the hEA and hAE fusion protein (presumably about 65 kDa in size) were very low and difficult to see in the SDS-PAGE (Fig 2A) . Therefore, the expressions of the fusion proteins were not clearly confirmed. To investigate its transcription level, RT-PCR was carried out to confirm the transcription of fusion genes. RT-PCR products of 0.6 kb, 1.0 kb, and 1.6 kb sizes were detected by agarose gel electrophoresis (data not shown). This fact suggests that transcription of the hES, hAS, hEA, and hAE genes occurred, but that the expression levels of the fusion proteins were lower than those of the single proteins. Furthermore, it was revealed that the expression level of the hAE fusion proteins was higher than its reverse hEA fusion proteins. At this time, the reasons for the low expressions levels of the fusion proteins are not clearly known.
The expressed recombinant proteins were purified by His-tag affinity column chromatography. Under nonmodified conditions, the molecular masses of hES, hAS, and fusion proteins were calculated from the deduced amino acid sequences as being 20 kDa, 40 kDa, and 60 kDa, respectively. However, the molecular sizes of purified recombinant proteins from P. pastoris expression had apparent molecular masses of 25 kDa, 55 kDa, and 65 kDa, respectively, on the SDS-PAGE (Fig. 2B ). These differences in protein sizes suggest that expressed recombinant hES, hAS, hEA, and hAE proteins in P. pastoris are modified with post-translational modifications such as glycosylation.
The authentic behaviors of purified proteins were then checked by Western blot and MALDI-TOF mass analyses. The culture supernatant of P. pastoris expression was subjected to Western blot analysis using a specific monoclonal antibody against endostatin (the alpha chain of type XVIII collagen) and angiostatin (kringle 1-4 of plasminogen). Single proteins of endostatin and angiostatin were detected by their specific antibodies, whereas the two fusion proteins (hAE and hEA) were only detected by the antiangiostatin antibody (Fig. 2C) . Moreover, expressed target proteins were cut from the gel and further analyzed by an electrospray quadrupoletime of flight (ESI-Q-TOF) mass analyzer (data not shown). The amino acid sequences of the hES and hAS proteins were identical with those of collagen XVIII and plasminogen precursor, which means that they were confirmed to be authentic human endostatin and angiostatin.
The efficacy of the two fusion constructs (hAS and hES) for their synergistic antiangiogenesis properties were investigated by employing both gene expression and protein delivery in HMEC-1 cells. For mammalian gene expression, 1 µg of recombinant pCIneo plasmids harboring the hAS, hES, hAE, and hEA genes were co-transfected with the pGL3-VEGF promoter plasmid into HMEC-1 cells. It was assumed that the transcriptional regulation of the VEGF promoter might be affected by the co-expression of human angiostatin (hAS), endostatin (hES), and the angiostatin-endostatin fusion constructs (hAS, hES). Owing to the fact that VEGF (vascular epidermal growth factor) is one of the key factors in angiogenesis, transcriptional suppression of VEGF promoters could be regarded as being the effect of expressed antiangiogenesis factors in HMEC-1 cells [9] .
For the luciferase assay, the human VEGF promoter (-2,865+ 955 relative to the transcription start site) was generated from human genomic DNA (Clontech, U.S.A.) by PCR using a forward primer (5'-CTTCCCCCAATCTGCTAGGT-3') and a reverse primer (5'-CTCGGCGAGCTACTCTTCCT-3'). It was then subcloned into the luciferase reporter vector pGL3basic.
HMEC-1 cells were plated at a density of 2×10 5 cells in 12-well plates, cultured for 1 day in DMEM supplemented with 10% FBS, and were transiently transfected with a pGL3-Basic (Promega) or a pGL3-VEGF promoter along with hAS or hES DNA constructs using Lipofectin (Invitrogen, U.S.A.). To correct the variance of transfection efficiency, a pCMV-beta-gal (Clontech, U.S.A.) was cointroduced. Their expressions were analyzed by using a BD Pharmingen Luciferase Assay and Detection System (BD Biosciences, U.S.A.) and a MicroLumat Plus LB96V luminometer (Berthold Technologies, Germany). Reporter activities were calculated after normalization with the transfection control (beta-galactosidase activity) and total protein, and presented as a relative light unit (RLU). To analyze the effects of purified AS or ES proteins, the protein treatment of cells was performed by adding a final concentration of 2.5 µg/ml of the protein to the cells at 24 h post-transfection for 24 h.
Transcriptional levels of the VEGF promoter were synergistically inhibited in the expression of the hAE angiostatic fusion gene (Fig. 3A) . Subsequently, the purified recombinant human angiostatin (hAS), endostatin (hES), and fusion proteins (hAE and hEA) were used to treat HMEC-1 cell cultures after 24 h transfection. Similarly, a combination regimen using equal amounts of hAE fusion proteins was shown to be more effective in VEGF promoter inhibition when compared with treatment with individual hAS and hES proteins (Fig. 3B) . Neither hEA gene expression nor hEA protein addition showed any synergistic effects.
DISCUSSION
The results indicate that the treatment of purified hAE proteins, as well as the gene expression of hAE fusion, suppressed the level of VEGF promoter activity greater than that of the hEA fusion construct. These results also indirectly suggest that the angiostatin-endostatin fusion construct (hAE) has a more potent antiangiogenic activity than the endostatin-angiostatin fusion construct (hEA), when determined from the effectiveness of VEGF promoter inhibition using luciferase reporter genes. Furthermore, the angiostatin-endostatin fusion construct (hAE) showed a greater effect in VEGF promoter inhibition, when compared with treatment using equal amounts of angiostatin (hAS) and endostatin (hES).
The initial expressions of human angiostatin-endostatin fusion proteins were tested in an Escherichia coli expression system. This system, providing rapid growth, a wellcharacterized genetic background, a high expression level, and a low cost, has been the most attractive and utilized system for heterologous protein expression [2] . The angiostatin-endostatin hybrid genes were initially evaluated for soluble expression using prokaryotic expression vectors such as pET15b, pET25b, and pMAL-c2e. However, all the approaches to express soluble proteins in E. coli failed owing to the accumulation of inclusion bodies in the cytoplasm, or the rapid loss of solubility of the fusion protein after protease cleavage (data not shown). Therefore, the Pichia pastoris expression system was used as an efficient host for the expression and secretion of angiostatinendostatin fusion proteins [5, 13] .
To date, there have been no reports regarding the comparative orientation effects of different angiostatinendostatin fusion proteins. This study was particularly focused on whether the order of each protein, in the fusion protein construction, has a significant effect. Previously, the combination of angiostatin and endostatin has been shown to have synergistic antiangiogenic and antitumor properties, when the genes for these proteins were delivered to tumor cells by retroviral gene transfer [18] . Subsequently, the construction of a murine angiostatin-endostatin fusion gene (Statin-AE), which shows enhanced antiangiogenic activity on human umbilical vein endothelial cell (HUVEC) tube formation in vitro, was compared with angiostatin and endostatin individually [18] . A. VEGF promoter activity regulated by angiostatin or endostatin DNA overexpression. B. VEGF promoter activity regulated by angiostain or endostain protein treatment. Data represent the mean ± SD of three separate experiments.
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In conclusion, two angiostatic fusion proteins (hAE and hEA) differing in tandem connection manners were constructed and expressed in Pichia pastoris. The authentic properties of the recombinant proteins were then checked by both Western blotting and mass spectrometry analyses. Purified recombinant fusion proteins (hAE, hEA), along with each single protein (hAS and hES), were added to verify the effect of the orientation, in addition to gene expression experiments. The luciferase assay, using a VEGF promoter, revealed that the angiostatin-endostatin fusion construct (hAE) showed a more potent inhibitory effect than the endostatin-angiostatin fusion construct (hEA) in both gene expression and protein delivery. The expression levels of fusion proteins were found to be relatively low when compared with those of single proteins such as endostatin and angiostatin. However, optimized culture conditions, or codon-optimized gene expression, could result in an elevated level of fusion expression [21] . Although the precise mechanism responding to these effects should be further studied, the angiostatin-endostatin fusion protein could be used for developing therapeutic proteins for anticancer agents.
